CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ)), a biopharmaceutical company focused on developing
XORTX Therapeutics Inc (XRTX) Appoints Ronald Perrone to its Board streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
XORTX Announces New Clinical Advisory Board Member tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
A recently published study by Future Market Insights predicts that the global autosomal dominant polycystic kidney disease treatment market will experience a value CAGR of 5.97% from 2023 to 2033, reaching an estimated value of US$ 2,140 million. The availability of special regulatory designations is one of the main.